Search

Displaying results 1311 - 1320 of 5384 in total
  1. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure. … [L31178] Although not the first sGC stimulator to be granted FDA approval ([riociguat] was approved in 2013 for use in pulmonary hypertension),[L3955] vericiguat is unique amongst its peers in that modifications

  2. Drug

    Mephenesin

    go.drugbank.com/drugs/DB13583
    ApprovedWithdrawn

    It first entered use in the 1950s.

  3. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite

  4. Drug

    Detomidine

    go.drugbank.com/drugs/DB11556
    InvestigationalVet approved

    This drug is prescribed by veterinarians and is marketed as _Dormosedan_. Currently, it is only approved by the FDA for use in horses but has been studied for use in other large animals.

  5. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469] … [A32019] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.

  6. Drug

    Asparaginase Escherichia coli

    go.drugbank.com/drugs/DB00023
    ApprovedInvestigational

    For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999]. … Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia

  7. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    [A232955, A232960] In December 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended cipaglucosidase alfa be granted marketing authorization for the treatment of Pompe disease … Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by

  8. Drug

    Beclomethasone dipropionate

    go.drugbank.com/drugs/DB00394
    ApprovedInvestigational

    [A179839] Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone dipropionate.

    Categories: Corticosteroids for inhalation use
  9. Drug

    Remimazolam

    go.drugbank.com/drugs/DB12404
    ApprovedInvestigational

    [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722]

  10. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully … Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group.